Refine Results
- view as grid
- view as list
How Full FDA Approval Could Spur Vaccination
In this Axios column, Drew Altman says full FDA approval of COVID-19 vaccines can provide a big boost to vaccination efforts if treated as an opportunity for updated messaging from government officials at all levels and public health experts and new actions from employers.
Perspective Read More
Vaccines Are Free. Covid Care Is Not. Who Should Pay?
In this commentary for Barron’s, Cynthia Cox explores the impact to the American public as the U.S. health insurance system adjusts to the COVID-19 pandemic. She uses the experience of the past year and a half to raise questions about broader issues of fairness in the distribution of health care costs in the country.
Perspective Read More
Why The California Recall Is Not a Harbinger of What Is to Come on COVID As a Campaign Issue
In this Axios column, Drew Altman examines the lessons for COVID-19 as a political issue from Governor Gavin Newsom’s resounding win in California’s recall election.
Perspective Read More
Where To Start To Build Vaccine Confidence
In this Axios column Drew Altman writes about the recent attention to Republican vaccine resisters. “Republicans and rural Americans are among the most resistant vaccine holdouts and some strategies are emerging to reach them.” But “far from all Republicans are resisters” and “the bigger and quicker payoff will come from prioritizing the more moveable group of ‘wait and see’ Americans.”
Perspective Read More
Why Low Growth in Health Costs Still Stings
This was published as a Wall Street Journal Think Tank column on April 8, 2015. In my last Think Tank piece, I reported that just 3% of Americans felt health costs had been rising more slowly than usual, even though they have been growing at record low rates in recent years. The…
Perspective Read More